- Patent Title: Compound for inhibiting binding between DX2 protein and p14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
-
Application No.: US16100226Application Date: 2018-08-10
-
Publication No.: US10280178B2Publication Date: 2019-05-07
- Inventor: Bum Joon Park , Gyu Yong Song , Ah-Young Oh , Jee-Hyun Lee , Jin-Hyuk Her
- Applicant: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION , THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
- Applicant Address: KR Busan KR Daejeon
- Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION,THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
- Current Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION,THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
- Current Assignee Address: KR Busan KR Daejeon
- Agency: Revolution IP, PLLC
- Priority: KR10-2014-0081396 20140630; KR10-2015-0092057 20150629
- Main IPC: C07D493/04
- IPC: C07D493/04 ; A61K31/366 ; G01N33/574 ; A61K31/352 ; A61K45/06 ; C12Q1/68 ; A61K31/35 ; A61K31/34
Abstract:
Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
Public/Granted literature
Information query
